First-Line Afatinib + Cetuximab for EGFR-Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Afatinib Plus Cetuximab for EGFR-Mutant Non-Small-Cell Lung Cancer: Results From the Randomized Phase 2 IFCT-1503 ACE-Lung Study
Clin. Cancer Res 2021 May 24;[EPub Ahead of Print], AB Cortot, A Madroszyk-Flandin, E Giroux Leprieur, O Molinier, E Quoix, H Berard, J Otto, I Rault, D Moro-Sibilot, J Raimbourg, E Amour, F Morin, J Hureaux, L Moreau, D Debieuvre, H Morel, A Renault, E Pichon, B Huret, S Charpentier, MG Denis, J CadranelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.